ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone ...

ABBOTT PARK, Ill., Sept. 28, 2020/ PRNewswire/-- Abbott, the worldwide leader in continuous glucose monitoring technology, ... The FreeStyle Libre 3 technology provides continuous, ...

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous glucose monitoring technology as the "Best ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class I, the most serious designation the agency can hand out for a recall.

The FreeStyle Libre flash glucose monitoring system (Abbott) measures interstitial fluid glucose levels. The system comprises a sensor and a reader. An optional companion app for Android mobile ...

Just months after FDA approved Abbott’s Freestyle Libre continuous glucose monitoring (CGM) system, which requires no regular finger sticks, Medicare will cover the product for certain seniors, ...

Abbott Laboratories won a CE mark for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, expanding its presence on the European diabetes market with a next-gen device.

Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books.

- Provides broader access to FreeStyle Libre system for residents living with diabetes in Ontario and Quebec - FreeStyle Libre is the first sensor-based glucose monitoring system to be listed in ...

Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System ™.The new icon-driven ...